None

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like Ozempic.

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes (T2D) and chronic kidney disease (CKD), addressing their cardiovascular (CV) and kidney disease risks.

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started a side hustle to afford it.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily used for managing type 2 diabetes, whereas Wegovy is specifically approved for weight loss.

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is a Hold.

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, potentially leading to serious health complications over time. Experts call for more research and a cautious approach to using these drugs,

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential impact on CKD.

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing significant insurance coverage disparities.

Utah Facial Plastics is transforming weight loss with Semaglutide and Tirzepitide, two proven treatments that help regulate appetite, improve insulin

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight loss treatment. It has shown remarkable results in reducing body weight, making it a popular choice for those struggling with obesity or overweight.